Ipamorelin
5mg
Selective GH secretagogue investigated in pulsatile GH-release literature.
$50.00
Explore → Shop
VIEW ALL PERFORMANCE
PERFORMANCE
Tesamorelin
10mg
$70.00
PERFORMANCE
Tesamorelin10mg
$70.00
Select Research Supply
| Bundle | Vials | Total | Per Vial |
|---|---|---|---|
| Single Vial | 1 | $70.00 | $70.00 |
| 4-Week Research Supply | 4 | $210.00 | $52.50 |
| Complete 8-Week Research Supply | 8 | $420.00 | $52.50 |
- Secure Checkout
- Fast Shipping
- Reference Materials
- Cold-Chain Protected
1 available · Ships within 48 hours
- Third-Party TestedThird-Party Tested
- Cold-Chain HandledCold-Chain Handled
- Concierge SupportConcierge Support
Questions about this compound, specifications, or documentation?
Speak with the ConciergeStabilized growth hormone-releasing hormone (GHRH) analog referenced in published literature investigating GHRH-receptor signaling and downstream IGF-1 pathway biology.
- GH/IGF-1 axis research
- Pulsatile GH-release literature
- Cold-chain handled, third-party tested
VIEW BATCH COA
Independent lab verification · current batch
- THIRD-PARTY TESTED
- COLD-CHAIN HANDLED
- TRACKED SHIPPING
- QUALITY-FOCUSED SOURCING
SPECIFICATIONS
- Product
- Tesamorelin
- Strength
- 10mg
- Vial Size
- 10mg per vial
- SKU
- VLR-TESA-10
- Batch / Lot
- Current batch listed on COA
- Storage
- Refrigerate 2–8°C · protect from light
- Form
- Lyophilized powder
RESEARCH USE ONLY
Sold strictly for laboratory and research purposes — never for human consumption, food, drug, or cosmetic use. 21+ only. A standard we hold ourselves to, not just the law.
EDUCATIONAL OVERVIEW
About this compound
Context, not noise — what the research actually says.
WHAT IT IS
A GH-secretagogue research peptide studied in pulsatile growth-hormone signaling literature.
PERFORMANCE
KEY BENEFITS
- Investigated in pulsatile GH-release research
- Studied across IGF-1 downstream signaling
- Referenced in growth-hormone axis literature
COMMON USES
- Growth-hormone axis studies
- Pulsatile GH-release research applications
- Layered with adjacent pathway compounds
THINGS TO KNOW
- Reconstitutes cleanly with BAC water
- Refrigerate after reconstitution; protect from light
- Research use only — not for human consumption
RELATED COLLECTION
Perform Research Collection
Pairs with Ipamorelin — Compounds referenced together in GH and IGF-1 signaling axis literature.
VIEW COLLECTION
COLLECTION PRICE
$90.00
STORAGE
Cold-chain handling
REFRIGERATED
Store unopened at 36–46°F (2–8°C).
RECONSTITUTED
Keep refrigerated. Do not freeze.
PROTECT FROM LIGHT
Original packaging until use.
Store unopened vials refrigerated at 36–46°F (2–8°C). After reconstitution, keep refrigerated and use within the timeframe specified by your laboratory practice. Protect from light. Do not freeze reconstituted solution.
SHIPPING
Shipping information
Insulated, tracked, and handled with care from our facility to yours.
PROCESSING
Ships within 48 hours of order confirmation.
COLD-CHAIN
Insulated packaging with ice packs for temperature-sensitive compounds.
TRACKED & INSURED
Tracking provided. Domestic delivery typically 2–5 business days.
Local pickup is available by appointment for customers in the Phoenix, Arizona area. See the full shipping policy for details, accepted payment methods, and scheduling.
FAQ
Common questions
SCIENTIFIC RESEARCH OVERVIEW · SRO
Scientific Research Overview
A structured summary of published scientific literature on this compound — provided for educational reference only.
Endocrine Research
RESEARCH SNAPSHOT
- Research Category
- Investigational synthetic growth-hormone-releasing hormone analogue
- Biological Targets
- Growth Hormone-Releasing Hormone (GHRH) receptor
- Growth Hormone/IGF-1 axis
- Primary Areas of Research
- Growth-hormone axis signaling · Pulsatile growth-hormone release · IGF-1 physiology · Visceral adipose tissue biology · Body composition research · Cardiometabolic risk markers
- Current Stage of Research
- Human Clinical Research
WHAT IS TESAMORELIN?
Tesamorelin is a synthetic 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) investigated in the scientific literature for its effects on the hypothalamic-pituitary-growth-hormone axis. It is designed to stimulate endogenous, pulsatile growth-hormone release via the GHRH receptor and has been studied in controlled human trials for its effects on body composition, visceral adipose tissue, and growth-hormone/IGF-1 axis markers.
PRIMARY AREAS OF RESEARCH
- Growth-hormone axis signaling
- Pulsatile growth-hormone release
- IGF-1 physiology
- Visceral adipose tissue biology
- Body composition research
- Cardiometabolic risk markers
- Published studies have investigated stimulation of endogenous, pulsatile growth-hormone release via the pituitary GHRH receptor in human trials.
- Research suggests changes in visceral adipose tissue and waist-circumference parameters in specific patient populations studied across multi-phase trials.
- Current evidence indicates dose-dependent increases in IGF-1 concentrations and growth-hormone pulse profiles in published clinical datasets.
- Investigators have observed effects on lipid-profile markers, liver-fat content, and inflammatory markers in some reported trial populations.
Tesamorelin is being studied for its ability to bind to pituitary GHRH receptors and stimulate physiologic, pulsatile growth-hormone secretion. Current evidence indicates that increased growth-hormone release promotes hepatic IGF-1 production and downstream anabolic signaling. Published work also suggests effects on visceral adipose tissue lipid handling and substrate partitioning, though the precise tissue-specific mechanisms remain under investigation.
CURRENT AREAS OF INVESTIGATION
- GH Axis
- IGF-1 Signaling
- Endocrine Research
- Metabolic Health
- Body Composition
- Healthy Aging
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. View source
- Falutz J, Mamputu JC, Pöttgens S, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2010;24(15):2389-2398. View source
- Stanley TL, Feldpausch MN, Oh J, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1312-1321. View source
- Makimura H, Stanley TL, Sun N, et al. Metabolic effects of long-acting growth hormone-releasing factor agonist (tesamorelin) in obese patients with and without obstructive sleep apnea. J Clin Endocrinol Metab. 2012;97(12):E1327-E1334. View source
- Bhatia R, Hastings C, Kriz G, et al. The effect of growth hormone-releasing hormone (tesamorelin) on cognitive function in healthy adults. J Clin Endocrinol Metab. 2016;101(4):1388-1394. View source
RESEARCH STATUS
This compound continues to be investigated in preclinical and/or clinical research. Scientific understanding continues to evolve as additional studies are published.
RESEARCH DISCLAIMER
For laboratory research use only. This information summarizes published scientific literature for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
RELATED · PERFORMANCE
More from this pillar
RESEARCH DISCLAIMER
All VELOR compounds are sold strictly for laboratory and research purposes only. They are not intended for human consumption, ingestion, or any food, drug, cosmetic, or therapeutic use. By purchasing, you confirm you are 21+ and a qualified researcher or research institution. Statements have not been evaluated by the FDA.
PERFORMANCE
Tesamorelin
$70.00
1